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Abstract
Background: Motor and sensory evoked potentials (EP) are potential candidate biomarkers for clinical
trials in multiple sclerosis.
Objective: To determine test -retest reliability of motor EP (MEP) and sensory EP (SEP) and associated
EP-scores in patients with multiple sclerosis.
Methods: In three centres, 16 relapsing and five progressive multiple sclerosis patients had MEPs and
SEPs 1–29 days apart. Five neurophysiologists independently marked latencies by central reading. By
variance component analysis, we estimated the critical difference (absolute reliability) for cross-
sectional group comparison, comparison of longitudinal group changes, within-subject minimal detect-
able change and defined within-subject improvement.
Results: Cortical SEP responses and cortico-muscular MEP latencies were more reliable than central
conduction times. For comparison of 20 subjects per arm, cross-sectional group difference ranged from
0.7 to 3.9 ms and 1.1 to 1.7, group difference in longitudinal changes from 0.4 to 1.8 ms and 0.36 to
0.62, within-subject minimal detectable change from 1.2 to 5.8 ms and 1.2 to 2.0, within-subject
improvement from 0.8 to 3.8ms and 0.8 to 1.3, for single EP modalities and EP scores, respectively.
Conclusions: Multicentre EP assessment with central EP reading is feasible and reliable. The critical
difference is reasonably low to detect significant group changes and to define responders. The results
support the concept of using EP and EP-scores as candidate response biomarkers for quantification of
disease progression and for studying remyelination in multiple sclerosis.
Keywords: Motor evoked potentials, sensory evoked potentials, biomarker, response biomarker,
progressive MS, remyelination, test–retest reliability, mean detectable change
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Introduction
For clinical trials in multiple sclerosis (MS) target-
ing disease progression and remyelination there is
still a need for surrogate outcomes. Such response
biomarkers have to be valid, reliable and sensitive to
change.1 Evoked potentials (EPs) have a high con-
struct and criterion validity2 reflected by their close
relationship to the pathophysiology of symptoms,3,4
and by the fact that EP scores derived from different
EP modalities closely correlate to clinical disability
and predict clinical course over up to 20 years.5–11 In
addition, EPs are unbiased for directional change,
while remaining specific for the neuronal function,
and thus can measure deterioration as well as
improvement. In the current study, we aimed to
determine the reliability of quantitative EP scores
as candidate response biomarkers for clinical trials
in MS.
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To define the capability of a measure for detecting
a real within-subject change it is important to differ-
entiate relative from absolute reliability.12,13
Relative reliability denotes the stability of a
value’s rank over time relative to the entire sample
and is valuable for diagnostic and prognostic pur-
poses. Absolute reliability depends on the measure-
ment error within the same subject and is important
for defining the minimal detectable change (MDC)
in a test–retest situation.14,15
In most studies on measures derived from
motor evoked potentials (MEPs) relative reliability
is reported.13 The absolute reliability of MEPs
is higher for latencies than amplitudes, and MDCs
in single subjects range from 0.7 to 3.5 ms in hand
muscles and from 1.8 to 1.9 ms in a leg muscle.16–18
In a large multicentre study, the mean within-subject
standard deviation (SD) was 0.85 ms in a hand
muscle and the relative inter-session variability
was below 10% for a leg muscle.19,20 In patients
with relapsing and chronic MS, the within-subject
intra-session variability was increased in 67% of
patients as compared to healthy subjects.21
Reliability studies in sensory evoked potentials
(SEPs) are scarce and old reports include less than
10 subjects in serial recordings.22,23 A large recent
trial showed high reliability for the N20 latency in
median SEPs with a mean within-subject SD of 0.48
ms.19 No recent study has reported on the reliability
of tibial SEPs.
The reliability of the combination of different EP
modalities, i.e. EP scores, has not been studied. In
the case of MS, EP scores better reflect the extent of
impaired signal propagation than single modalities
due to the disseminated pathology of MS, and long
tracts have a higher probability to be altered.
Numerical scores calculated from z-transformed EP
latencies have been reported to have higher sensitiv-
ity to change than ordinal or semiquantitative
scores;24 however, they may be prone to higher mea-
surement variability.
In the current three centre study, we addressed
the measurement variability of SEPs, MEPs and
EP scores in a group of patients with relapsing–
remitting, secondary and primary progressive MS.
We employed a novel standardised recording
protocol, a custom-made server-based software
for standardised curve reading (EPMark) and a
statistical variance component analysis. We deter-
mined the critical difference for a cross-sectional
group comparison, for comparison of longitudinal
changes between two groups, and the MDC and,
furthermore, suggest a definition of a within-
subject improvement.
Participants and methods
Participants
The study was approved by the local institutional
review boards at the three participating study sites
(Basel, Dusseldorf, Gatineau) and was conducted
according to International Conference on
Harmonisation Good Clinical Practice (ICH-GCP)
guidelines. All participants gave written informed
consent. Inclusion criteria comprised a diagnosis of
MS (all phenotypes), an Expanded Disability Status
Scale (EDSS) between 0 and 6.5 and absence of a
relapse for at least 3 months. Exclusion criteria
included change in medications which possibly
interfere with signal propagation (sodium or potas-
sium channel antagonists and spasmolytics), comor-
bidities, which may affect testing (polyneuropathy,
cervical stenosis and morbid obesity among others)
and contraindication to MEP recording (epilepsy,
movable metal implants).
Recording
Patients were recorded twice at the same centre
with an interval of one to 30 days. Recording of
single EP modalities followed closely the recom-
mendations of the International Federation of
Clinical Neurophysiology.25–27 The protocol was
optimised for fast and robust acquisition to be feasi-
ble in a multicentre setting and the montage for
SEPs, as well as the placement of electrodes, coil
size and level of pre-innervation of the target muscle
for MEPs were standardised (for details see
Supplementary file 1). The recording of one limb
in one modality is referred to as a ‘test’; hence, a
subject has a set of eight tests per time point.
Rating of curves
Curves were coded and uploaded to a custom server-
based software application (EPMark, Supplementary
file 2), which displays curves in a standardised fash-
ion for central reading. All curves were evaluated by
experienced neurophysiologists (PA, PF, MH, FJ,
LL) blinded to clinical details, and markers were
set manually for cortico-muscular (CxM) and
spino-muscular (SpM) latencies in MEPs and for
peaks of the main cortical (N20, P40), cervical
(N13) and lumbar (N22) responses as well as Erb
in SEPs. Follow-up rating was done blinded to base-
line results after a delay of at least one week.
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Curves were excluded if less than three (out of five)
raters considered the N20 or the P40 peak or the
onset latency as valid. In addition, a MEP test was
only included if at least three (out of eight to 10)
MEP curves were valid.
Definition of EP parameters and quantitative
EP scores
Central conduction is the most important EP mea-
sure for diagnostic purposes in MS but is possibly
prone to more variability as it is the difference of
two measured values (overall and peripheral conduc-
tion times). At first-level analysis we therefore eval-
uated the reliability of both, central and overall
latencies as well as two different approaches to
define MEP onset latency. At second-level analysis,
the most reliable single EP tests were aggregated to
quantitative EP scores to yield one-dimensional
measures for statistical analysis.
In median SEPs (SEP-M), the cortical N20 and cen-
tral conduction times (CCTs; CCT-M1¼ latency
(N20–N13), CCT-M2¼ latency (N20–Erb)) were
used for statistical analysis, in tibial SEPs (SEP-T)
the cortical P40 and the CCT-T (CCT-T¼ latency
(P40–N22)). In MEPs the shortest CxM (shortest
latency of at least three curves), mean CxM (mean
of at least four curves), and central motor conduction
time (CMCT; shortest CMCT¼ shortest CxM-
shortest SpM; mean CMCT¼mean CxM-shortest
SpM) were analysed for upper limbs (ULs) and
lower limbs (LLs).
The method to calculate quantitative EP scores has
been described previously.5,8 Scores equal the sum
of z-transformed latencies of each included test divid-
ed by the number of tests. They are in the z-space and
dimensionless. In the current study, we calculated the
EP score without visual evoked potentials (VEPs) and
included N20, P40 and CxM instead of CCT and
CMCT, as the former show higher reliability at first-
level analysis. Two versions of the modified quantita-
tive EP score (mqEPS) were evaluated, the mqEPS-
short comprises: z-N20, z-P40, shortest z-CxM from
MEP-UL and MEP-LL, the mqEPS-mean: z-N20,
z-P40, mean z-CxM from MEP-UL and MEP-LL.
Accordingly, we calculated scores based on MEPs
(qMEP-short, qMEP-mean) and on SEPs (qSEP).
For transformation in z-space, published normative
values were used (Supplementary file 3a).
Statistical analysis
To describe the concordance for test and retest, we
calculated Spearman’s correlation coefficients for
each rater and side in MEPs and SEPs, and for
each rater in quantitative EP scores. To explore
data distribution, we used Bland–Altman plots and
inspected them visually.28
We used linear mixed effects models with the results
of test and retest assessment as the combined out-
come and included random factors to estimate the
different variance components. For single EP modal-
ities, the model comprised nine random factors
(rater, subject; subject*time, subject*rater, subject*-
side, rater*time (two-way interactions); subject*ra-
ter*time; subject*side*rater; subject*side*time
(three-way interactions) and an error term (i.e. sub-
ject*side*rater*time). As EP scores already include
the factor ‘side’, the corresponding models comprise
six factors. The factor ‘site’ was not considered as
only three sites participated rendering the estimate of
site variability unreliable.
We calculated the standard error (SE) for a cross-
sectional comparison between two groups (SEcross),
for a comparison of mean longitudinal change between
two groups (SElong) assuming equal sized groups with
equal data distribution. In addition, SE was calculated
for a longitudinal within-subject comparison (SE1S).
The case of two raters was assumed who independent-
ly mark all curves of all subjects corresponding to a
central reading in a study setting (without consensus
reading). Variance components and the weights for
defining the three SEs, which were calculated as the
square root of the respective sum of variance compo-
nents are given in Supplementary file 3b.
The critical difference D0 is given as the product of
SE by the respective quantile of the standard normal
distribution za defined by the selected alpha level,
yielding Dp¼ SE*zp. D0 is the value distinguishing
values of D compatible with the null hypothesis of
no real change from values of D where there is evi-
dence for a true change.
We assumed a two-sided testing with an alpha level
of 5% for group comparisons yielding Dcross=
SEcross*1.96 and Dlong¼SElong*1.96. For change
within a single subject we applied the definition of
the MDC14 giving DMDC¼SE1S*1.96. To increase
sensitivity, we additionally calculated a critical dif-
ference for improvement (or progression), for which
we considered a one-sided test at an alpha level of
10% as justified, yielding Dimp¼SE1S*1.24.
Results
Twenty-two subjects were recruited (Basel: nine,
Dusseldorf: five, Gatineau: eight), one had no
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follow-up exam and was excluded from analysis. The
remaining subjects had a median age of 51.0 years
(range 20.4–65.3) and 43% were men; 76.2%
(n=16) had a relapsing–remitting, 14.3% (n=3) a sec-
ondary progressive and 9.5% (n=2) a primary progres-
sive disease course. Different disease courses were
included to cover the full range from normal to severe-
ly pathological EPs which are more likely in
progressive patients. The median disease duration
was 9.2 years (range 0.2–40.3), median EDSS 3.0
(range 0–6.5) and last relapse at least a year ago
except in three patients (relapse between 80 and 93
days prior to baseline). Disease-modifying and symp-
tomatic treatments remained unchanged during
the study.
The median time between recordings was 8 days
(range 1–29 days). Table 1 shows the number of
tests per modality used for analysis. One subject
refused recording of tibial SEPs.
Fifty-nine per cent of subjects had at least one path-
ological test (one to two path. tests: 22.7%; three to
four path. tests: 27.3%; more than four path. tests:
9.1%). SEP-T had the highest yield of pathology
(P40: 51.3%, CCT-T: 42.9%), then MEP-LL (short-
est CxM: 28.6%, shortest CMCT: 33.3%) and MEP-
UL (shortest CxM: 22.7%, shortest CMCT: 29.6%);
SEP-M had only a few pathologies in CCT (N20:
0%, CCT-M: 6.8%).
Table 1. Number of tests per modality used for
analysis, left and right sides combined.
Baseline
(n¼ 22)
Follow-up
(n¼ 21)
MEP-UL 44 40
MEP-LL 42 40
SEP-M 44 42
SEP-Ta 39 37
UL: upper limb; LL: lower limb; M: median; T: tibial.
aOne subject did not take part in SEP-T.
Table 2. Spearman’s correlation coefficient for the association between test and re-test in single EP
modalities and EP scores.
(a) MEP-UL MEP-LL
CxM CMCT CxM CMCT
Shortest Mean Shortest Mean Shortest Mean Shortest Mean
Median 0.85 0.92 0.75 0.79 0.87 0.93 0.73 0.71
Min 0.80 0.91 0.65 0.75 0.76 0.86 0.65 0.60
Max 0.90 0.94 0.79 0.85 0.89 0.94 0.78 0.79
(b) SEP-M SEP-T
N20 CCT-M1 CCT-M2 P40 CCT-T
Median 0.92 0.54 0.73 0.79 0.74
Min 0.83 0.44 0.70 0.77 0.63
Max 0.93 0.67 0.80 0.81 0.77
(c) Multimodal qEPS Unimodal qEPS
mqEPS-short mqEPS-mean qMEP-short qMEP-mean qSEP
Median 0.91 0.92 0.93 0.94 0.80
Min 0.86 0.84 0.83 0.89 0.78
Max 0.96 0.95 0.96 0.97 0.83
Spearman’s rho was determined in each rater and side separately, and median and range is given for single EP
modalities and for quantitative EP scores ((a) MEP upper (UL) and lower limb (LL), cortico-muscular latency (CxM)
and central motor conduction time (CMCT) determined from shortest or the mean of MEP curves of one test; (b)
median (SEP-M) and tibial SEP (SEP-T) with central conduction time (CCT) determined from N20-CV7 (M1) or N20-
EP (M2); (c) modified quantitative EP score (mqEPS) and quantitative MEP score (qMEP) from shortest and mean
MEP curves, quantitative SEP score (qSEP)).
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Figure 1. Each scatterplot gives an overall impression of the association between test and retest rating in each evoked potential (EP) modality
pooled across sides (circles: left; points: right) and raters (colours) ((a) shortest and (b) mean cortico-muscular latency (CxM) for upper limb motor
EPs (MEP-UL); (c) shortest CxM and (d) mean CxM for lower limb MEPs (MEP-LL); (e) N20 for median SEPs (SEP-M); (f) P40 for tibial SEPs
(SEP-T). Diagonal lines represent perfect concordance between test and retest. Correlational analysis was run on each rater and side separately (2
_ 5 times per measure), median Spearman’s rho correlation coefficient is given (please refer to Table 2 and to Supplementary Figure 1 for
further details).
Hardmeier et al.
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Correlational analysis
Table 2 gives the median (range) rho of all readers
and sides; Figure 1(a–f) and Supplementary Figure 1
show the related scatterplots. In MEPs, CxM showed
higher concordance as compared to CMCT, and
mean CxM higher concordance than the shortest
CxM. In SEPs, N20 and P40 showed higher concor-
dance than CCT-M1, CCT-M2 and CCT-T. The con-
cordance of EP scores was generally high except for
qSEP, and slightly higher in scores based on mean
CxM compared to shortest CxM. Visual inspection
of the Bland–Altman-plots (Supplementary
Figure 2) did not reveal any systematic deviations
in the sense of heteroscedasticity, particularly no
indication that variability between test–retest is
higher in more pathological EPs.
Variance components from mixed linear
effect models
Models were calculated on the measures with high-
est concordance. Total absolute variance and vari-
ance components are given in Tables 3 and 4.
Subject-related variance components explained
most of the overall variability in single EP modali-
ties (SEP-T: 73%; SEP-M: 81%; MEP-UL shortest
CxM: 89%, and >90% in the remainder) and in
quantitative EP scores (>90%, except qSEP:
76%). Rater-related variance (including the error
term) explained the following proportion of variabil-
ity: MEPs up to 5.5%, SEP-M: 10%, SEP-T: 16%;
mqEPS-short: 6.9%, mqEPS-mean: 5.8%, qMEP-
short: 3.9%, qMEP-mean: 2.2%, qSEP: 12%.
Measurement-related variability and critical
difference D
Tables 3 and 4 give the SE for single EP modalities
and EP scores for a comparison of two equal sized
groups with 20 subjects per arm cross-sectionally
(SEcross), in regard to their longitudinal change
(SElong) and for a within-subject longitudinal com-
parison (SE1S; n=1) with respective critical differ-
ences (DMDC, Dimp). For MEPs, mqEP and qMEP
two values are given: the first refers to scores includ-
ing the shortest CxM, the second to scores including
mean CxM.
With 20 subjects per arm, a cross-sectional group
difference (Dcross) of 2.3 and 2.4 ms in MEP-UL,
3.7 and 3.9 ms in MEP-LL, 0.7 ms in SEP-M and
3.3 ms in SEP-T, and group difference in longitudi-
nal changes (Dlong) of 0.9 and 0.8 ms in MEP-UL,
1.1 and 0.8 ms in MEP-LL, 0.4 ms in SEP-M and
Table 3. Variance components from linear mixed effect models for single EP modalities.
(a) MEP-UL MEP-LL SEP-M SEP-T
Shortest CxM Mean CxM Shortest CxM mean CxM N20 P40
Total Var (ms) 13.80 14.89 36.37 39.30 1.30 31.44
S 9.75 11.47 29.79 33.42 0.89 22.73
R 0.06 0.12 0.13 0.19 0.01 0.25
S*T 0.03 0.09 0.34 0.24 0.09 3.25
S*R 0.01 0.00 0.00 0.02 0.00 0.74
S*L 2.60 2.35 3.88 4.43 0.16 0.16
R*T 0.05 0.00 0.12 0.02 0.01 0.01
S*R*T 0.15 0.10 0.34 0.15 0.07 0.82
S*L*R 0.00 0.00 0.14 0.05 0.00 2.38
S*L*T 0.67 0.55 0.64 0.38 0.02 0.31
Error 0.50 0.20 0.99 0.41 0.04 0.81
SEcross 1.16 0.85 1.33 1.39 0.25 1.20
SElong 0.45 0.40 0.57 0.42 0.19 0.93
SE1S 1.45 1.25 1.85 1.35 0.59 2.96
DMDC 2.83 2.46 3.62 2.64 1.16 5.80
Dimp 1.85 1.60 2.36 1.72 0.76 3.79
Total variance and single variance components including interaction terms are given in the upper part (Var: variance;
S: subject; R: rater; T: time; L: side).
UL: upper limb; LL: lower limb; SEP-M: median SEP; SEP-T: tibial SEP; CxM: cortico-muscular latency.
Related standard errors (SEcross, SElong, SE1S) and critical differences (DMDC, Dimp) are given in bold, please refer to
the main text for details.
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1.8ms in SEP-T reflects a statistically significant
change at an alpha level of 5%. Values in EP
scores are lower: 1.2 and 1.2 in mqEPS, 1.6 and
1.7 in qMEP and 1.1 in qSEP for Dcross, and 0.39
and 0.36 in mqEPS, 0.48 and 0.37 in qMEP and 0.62
in qSEP for Dlong. These values decrease by 50% if
the group size is quadrupled.
MDC is relatively high with values of 2.8 and 2.5 ms
in MEP-UL, 3.6 and 2.6 ms in MEP-LL, 1.2 ms in
SEP-M and 5.8 ms in SEP-T, MDC in EP scores is
lower: 1.6 and 1.5 in mqEPS, 1.5 and 1.2 in qMEP
and 2.0 in qSEP.
For a more sensitive detection of improvement or
progression, a one-sided testing at an alpha level
of 10% yields lower critical differences. Dimp are
1.9 and 1.6ms in MEP-UL, 2.4 and 1.7 ms in
MEP-LL, 0.8ms in SEP-M and 3.8ms in SEP-T.
For EP scores Dimp are 1.1 and 1.0 in mqEPS, 1.0
and 0.8 in qMEP and 1.3 in qSEP.
Discussion
Based on a sample of 21 MS patients with relapsing
and progressive disease course we investigated the
measurement variability of SEPs, MEPs and associ-
ated quantitative EP scores with a median test–retest
interval of 8 days using a standardised recording
protocol in three centres. As pathological changes
during such a period are unlikely, the within-
subject test–retest differences define the measure-
ment error. To account for physiological and rater
variability, each curve was independently assessed
by each of the five raters using a custom-made
server-based software (EPMark), and retest reading
was done blinded to baseline results.
First-level analysis showed that the main cortical
responses in SEPs and the cortico-muscular latencies
in MEPs have lower measurement error than the
central sensory and motor conduction times, which
has been shown previously for MEPs.16 This result is
most likely due to the fact that central conduction is
determined as the difference of overall and periph-
eral conduction in which the latter introduces addi-
tional variability into the measurement. The
distinction between central and peripheral conduc-
tion yields important diagnostic information.
However, in the context of a longitudinal within-
subject assessment in patients with MS the situation
is different. Here, changes in the overall conduction
are attributable to the central part as peripheral con-
duction can be assumed to remain stable except in
patients with concomitant diseases such as myelop-
athy not due to MS, diabetic and other polyneuropa-
thies among others. However, these patients are
usually excluded from participation in clinical trials.
Table 4. Variance components from linear mixed effect models for quantitative EP scores
Multimodal qEPS Unimodal qEPS
mqEPS-short mqEPS-mean qMEP-short qMEP-mean qSEP
Total Var (ms) 3.63 3.91 6.39 7.34 3.17
S 3.27 3.58 5.93 7.05 2.42
R 0.03 0.04 0.05 0.08 0.03
S*T 0.11 0.11 0.21 0.14 0.37
S*R 0.03 0.06 0.00 0.00 0.09
R*T 0.01 0.00 0.03 0.00 0.01
S*R*T 0.00 0.00 0.00 0.00 0.00
Error 0.18 0.13 0.17 0.08 0.25
SEcross 0.69 0.75 0.79 0.85 0.54
SElong 0.26 0.24 0.24 0.19 0.32
SE1S 0.83 0.76 0.78 0.60 1.00
DMDC 1.62 1.49 1.54 1.18 1.96
Dimp 1.06 0.98 1.00 0.77 1.28
Total variance and single variance components including interaction terms are given in the upper part (Var: variance;
S: subject; R: rater; T: time; mqEPS: modified quantitative EP score; qMEP: quantitative MEP-score; qSEP: quan-
titative SEP score).
Related standard errors (SEcross, SElong, SE1S) and critical differences (DMDC and Dimp) are given in bold, please refer
to the main text for details.
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Due to pre-innervation for facilitation, MEPs can
exhibit baseline fluctuations and the rater has to
make some estimations regarding the onset.
Physiologically, fluctuations in cortical and spinal
excitability influence the spatial and temporal
summation of incoming volleys at the spinal moto-
neuron.27 Experimentally, the mean within-session
trial-to-trial difference has been shown to amount
to 0.59ms (SD 0.17) in healthy controls and to
1.49ms (SD 1.23) in patients with MS and the
authors have even proposed to use this variability
as a diagnostic sign.21 Therefore, the mean instead
of the shortest cortico-muscular latency has advan-
tages for longitudinal within-subject comparisons,
and averaging has been shown to increase reliabili-
ty.29 Rater-related variability is potentially reduced
by consensus reading of discrepant curves and by
rating with comparison to previous curves. To
account for rater-related variability, we deliberately
renounced from these procedures. However, com-
parison of successive curves is especially important
in SEPs in which the higher measurement error in
our study is in large part due to single outlying sub-
jects with ambiguous peaks.
The yield of pathological tests is important for mea-
suring a therapeutic response on slowed conduction.
The chance of a pathologically prolonged latency
correlates with the length of the tract as also
shown in our data, in which the rate of pathological
results was slightly lower compared to rates reported
in the literature in more advanced patients.6,30
At second-level analysis, we determined the mea-
surement variability and estimated the critical differ-
ence for group and single subject settings assuming a
central reading by two independent raters.
In single EP modalities, the critical difference for a
cross-sectional comparison of 20 subjects per arm
lies around 2 ms for cross-sectional and around
1ms for comparison of longitudinal changes, and
is numerically lower in quantitative EP scores.
Achieving such group differences seems to be
likely given the results of two recent VEP
trials.31,32 They have demonstrated a mean differ-
ence in longitudinal changes by 6.1 ms at 32
weeks in favour of patients treated with opicinumab
and a mean within-subject shortening of the VEP
latency by 1.7 ms under treatment with clemastine.
In an observational study, a quantitative EP score
increased from 2.6 to 3.5 in a sample of 72 relapsing
and progressive MS patients after one year.24
At the single subject level, the context of use and the
translation into clinical relevance has to be consid-
ered when deciding on the false positive rate. The
minimal detectable change (two-sided, alpha level:
5%)14 is numerically quite high and a patient with a
change in a single modality of more than 3 ms or a
change in a quantitative EP score of more than 1.5 is
very likely also to have signs of clinical progression
(Figure 3 in Hardmeier et al.).11 In clinical practice,
sensitive measures are required to identify patients
before they progress, and in clinical studies, which
compare responder rates between treatment arms as
the primary outcome, a higher event rate may be
preferable at the cost of some specificity. In both
settings, a one-sided testing would be appropriate
and a false positive rate of 10% acceptable, resulting
in a critical difference in the range of 1.6–2.4 ms for
single EP modalities (except SEP-T: 3.8 ms) and in
the range of 0.8–1.3 for quantitative EP scores.
Depending on the interval between the assessments
and the effects of an intervention, these numbers
seem to be realistic. More empirical data have to
be gathered to determine the clinical relevance of
these cut-offs. However, a 6-month change in a
quantitative EP score is predictive of an EDSS pro-
gression at 3 years at the group level.24
EP scores may have several advantages over single
EP modalities. Their validity is higher as they are
more closely associated with overall clinical disabil-
ity. As the mean of several tests, they are less influ-
enced by single outlying tests and less prone to
selection bias. The latter may occur if only the path-
ological tests of a multimodal assessment are taken
at baseline to measure treatment effects at follow-up
as a regression to the mean may simulate improve-
ment.33 However, systematic effects related to the
state of the subject may sum up in a score. In
stable patients, fluctuations of cortical and spinal
excitability seem to play on a time scale of seconds
rather than days,21 as the reported intra-session
variability in MEPs is quite comparable to the
inter-session variability determined in our study. In
contrast, disease activity may influence cortical
excitability,34 and a conduction block in an affected
tract clearly changes the EP response. No measur-
able effect on EP latencies has been demonstrated in
fatigue making it unlikely to be a confounding
factor,35,36 while sodium blocking agents and 3-4-
aminopyridine probably are. In our study, EPs were
recorded at least 80 days after a last relapse and we
controlled for change in potentially confounding
medication. Hence, we consider the absolute
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reliability determined in our sample a realistic esti-
mate for studies in MS.
Some limitations have to be acknowledged. While
magnetic and electric stimuli are well standardised
and robust to hardware and software updates, record-
ing of EPs is time consuming and accuracy depends
on the strict adherence to the recording protocol.
The reading of EP curves still needs experienced
neurophysiologists, who, however, can mark curves
on a standardised display totally independent from
each other and blinded to clinical information by
using EPMark. While test–retest studies frequently
have only samples of less than 20 subjects,13 a larger
sample would have given closer estimates of the
variance components in our model. However, as
these components clearly differ from each other
qualitatively, different conclusions from our data
are quite unlikely. The responsiveness of EP scores
to therapeutic interventions are currently not well
known whereas sensitivity to change has been
shown several times in groups of patients.11
Conclusions
In summary, standardised multicentre EP assessment
with central reading is feasible and reliable. Mean
cortico-muscular latency in MEPs and the main cor-
tical responses in SEPs have higher reliability com-
pared with central conduction times. EP scores
are less influenced by outlying tests and are more
closely related to overall clinical disability. A com-
parison of longitudinal changes between two groups
has a smaller critical difference than a cross-sectional
comparison. In both settings, significant group
changes seem realistically achievable in small sam-
ples. At a single subject level, the cut-offs defining
improvement or progression with sufficient sensitivity
remain to be determined. The results support the con-
cept of using EPs as a candidate response biomarker
in clinical trials in MS for quantification of disease
progression and for studying remyelination. As our
tool for central reading of multimodal EPs
(EPMark) is operational, larger multicentre trials are
warranted to corroborate the current results and to
determine the mean longitudinal change in EP
scores in well-defined patient cohorts for precise
sample size estimation.
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